Stock Scorecard
Stock Summary for Pacira BioSciences Inc (PCRX) - $17.03 as of 11/20/2024 8:34:09 PM EST
Total Score
9 out of 30
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for PCRX
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for PCRX
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for PCRX
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 | |
Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for PCRX
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Safety Rating Criteria for PCRX (38 out of 90)
Stock Price Rating (Max of 10) | 6 |
Historical Stock Price Rating (Max of 10) | 9 |
Stock Price Trend (Max of 10) | 1 |
Book Value (Max of 10) | 6 |
Book Value to Price (Max of 10) | 2 |
Analyst Buy Ratings (Max of 5) | 2 |
Analyst Strong Buy Ratings (Max of 5) | 4 |
Dividend Yield Percentage (Max of 10) | 0 |
Operating Margin (Max of 10) | 3 |
Trading Volume (Max of 10) | 5 |
Price to Earnings (Max of 10) | 0 |
Latest News for for PCRX
Financial Details for PCRX
Company Overview |
|
---|---|
Ticker | PCRX |
Company Name | Pacira BioSciences Inc |
Country | USA |
Description | Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare professionals and their patients in the United States. The company is headquartered in Parsippany, New Jersey. |
Sector Name | LIFE SCIENCES |
Industry Name | PHARMACEUTICAL PREPARATIONS |
Most Recent Quarter | 9/30/2024 |
Next Earnings Date | N/A |
Stock Price History |
|
Last Day Price | 17.03 |
Price 4 Years Ago | 59.84 |
Last Day Price Updated | 11/20/2024 8:34:09 PM EST |
Last Day Volume | 466,592 |
Average Daily Volume | 564,184 |
52-Week High | 35.95 |
52-Week Low | 11.16 |
Last Price to 52 Week Low | 52.60% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 22.60 |
Sector PE | 40.32 |
5-Year Average PE | 16.07 |
Free Cash Flow Ratio | 1.73 |
Industry Free Cash Flow Ratio | 12.03 |
Sector Free Cash Flow Ratio | 27.97 |
Current Ratio Most Recent Quarter | 2.25 |
Total Cash Per Share | 9.83 |
Book Value Per Share Most Recent Quarter | 16.24 |
Price to Book Ratio | 1.02 |
Industry Price to Book Ratio | 5.31 |
Sector Price to Book Ratio | 20.88 |
Price to Sales Ratio Twelve Trailing Months | 1.11 |
Industry Price to Sales Ratio Twelve Trailing Months | 11.82 |
Sector Price to Sales Ratio Twelve Trailing Months | 7.11 |
Analyst Buy Ratings | 1 |
Analyst Strong Buy Ratings | 2 |
Share Statistics |
|
Total Shares Outstanding | 46,173,200 |
Market Capitalization | 786,329,596 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Total Years Dividend Increasing | N/A |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | -24.50% |
Annual Earnings Growth | 163.72% |
Reported EPS 12 Trailing Months | -1.98 |
Reported EPS Past Year | 2.30 |
Reported EPS Prior Year | 2.92 |
Net Income Twelve Trailing Months | -98,759,000 |
Net Income Past Year | 41,955,000 |
Net Income Prior Year | 15,909,000 |
Quarterly Revenue Growth YOY | 2.80% |
5-Year Revenue Growth | 13.54% |
Operating Margin Twelve Trailing Months | 0.13 |
Balance Sheet |
|
Total Cash Most Recent Quarter | 453,810,000 |
Total Cash Past Year | 278,581,000 |
Total Cash Prior Year | 288,651,000 |
Net Cash Position Most Recent Quarter | -133,547,000 |
Net Cash Position Past Year | -243,856,000 |
Long Term Debt Past Year | 522,437,000 |
Long Term Debt Prior Year | 689,471,000 |
Total Debt Most Recent Quarter | 587,357,000 |
Equity to Debt Ratio Past Year | 0.62 |
Equity to Debt Ratio Most Recent Quarter | 0.56 |
Total Stockholder Equity Past Year | 870,130,000 |
Total Stockholder Equity Prior Year | 775,010,000 |
Total Stockholder Equity Most Recent Quarter | 749,583,000 |
Free Cash Flow |
|
Free Cash Flow Twelve Trailing Months | -8,463,000 |
Free Cash Flow Per Share Twelve Trailing Months | -0.18 |
Free Cash Flow Past Year | 139,488,000 |
Free Cash Flow Prior Year | 115,198,000 |
Options |
|
Put/Call Ratio | 0.00 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | 0.27 |
MACD Signal | 0.38 |
20-Day Bollinger Lower Band | 10.87 |
20-Day Bollinger Middle Band | 16.56 |
20-Day Bollinger Upper Band | 22.24 |
Beta | 0.82 |
RSI | 48.27 |
50-Day SMA | 24.66 |
150-Day SMA | 40.71 |
200-Day SMA | 45.94 |
System |
|
Modified | 11/19/2024 9:50:29 AM EST |